A Phase 4 interventional study of ALBIS and Placebo in Gastritis and Gastroduodenal Ulcer, sponsored by Young-Hak Kim, MD, PhD. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-03-22.
Sponsored by Young-Hak Kim, MD, PhD · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Gastritis with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Gastritis · Korea, Republic of.
Among the 32 studies in Gastritis with a site in Korea, Republic of, this one is the 21st largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2015, is one of 5 in phase 4, and was the 8th registered.
136 studies on the registry are indexed under Gastritis; 24 are open to participants now.
Browse Gastritis studies →3 of the 32 studies in Gastritis with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–75
Korea Otsuka Pharmaceutical Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Addpharma Inc. · Sites in Korea, Republic of
Ages 19–50 · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 11 Gastritis studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 200 across 97 interventional studies indexed under Gastritis.
Median enrollment 242 across the 25 interventional studies, 585 across the 7 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 10 most frequent:
Young-Hak Kim, MD, PhD is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Young-Hak Kim, MD, PhD has 1 study filed under Gastritis — fewer than ten, so there is no comparison to draw.
1 of the studies in Gastritis with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07717775Addpharma Inc.A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Gastritis with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate effectiveness of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Albis Tab 2 tab twice a day 12weeks
Drug: ALBIS
placebo Tab 2 tab twice a day 12weeks
Drug: Placebo
Incidence of gastric ulcer
defined as a mucosal break of at least 5 mm in diameter(measured by gastrointestinal endoscopy) with depth, at 12weeks
Time frame: 12weeks
Incidence of gastritis
defined as Modified Lanza Score(MLS) grade 2\~4(measured by gastrointestinal endoscopy)at 12weeks
Time frame: 12weeks
The Endoscopic improvement rate of hemorrhage
defined as Modified Lanza Score(MLS) grade
Time frame: 12weeks
The Endoscopic improvement rate of subjective symptom
Time frame: 12weeks
Total amount of antacid used during study period
Time frame: 12weeks
Ran from Jan 2015 to primary completion in Dec 2018, 46 months.
Of 14 phase 4 interventional studies under Gastritis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 46 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Young-Hak Kim, MD, PhD